• Mutation; HGNC; HGNC:5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line).
  

PubMed=10679914; DOI=10.1002/(SICI)1098-2264(200003)27:3<252::AID-GCC5>3.0.CO;2-9
Gildea J.J., Golden W.L., Harding M.A., Theodorescu D.
Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer.
Genes Chromosomes Cancer 27:252-263(2000)

PubMed=12460916
Harding M.A., Arden K.C., Gildea J.W., Gildea J.J., Perlman E.J., Viars C., Theodorescu D.
Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling.
Cancer Res. 62:6981-6989(2002)

PubMed=15520187; DOI=10.1158/0008-5472.CAN-04-0826
Nicholson B.E., Frierson H.F. Jr., Conaway M.R., Seraj J.M., Harding M.A., Hampton G.M., Theodorescu D.
Profiling the evolution of human metastatic bladder cancer.
Cancer Res. 64:7813-7821(2004)

PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)